ArticleWorld journal of surgical oncology2026
Maximum standardized uptake (SUVmax) is associated with pathologically upstaged and recurrence-free survival in non-small cell lung cancer after curative surgery.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTimely detection of early-stage lung cancer via screening programs has improved, but unexpected advanced disease might exist and influence the prognosis. This study aimed to investigate the association between positron emission tomography (PET) maximum standardized uptake (SUVmax) and pathological upstaging and survival in patients with clinical stage IA (T1N0M0) non-small cell lung cancer (NSCLC).
methodsWe retrospectively reviewed patients with clinical stage IA NSCLC who underwent preoperative PET scans and curative surgery at Kaohsiung Veterans General Hospital from January 2015 to December 2021. The primary outcome was the rate of pathological upstaging, and a Cox regression model was used to identify prognostic factors for recurrence-free survival (RFS).
resultsIn total, 112 cases were included in this analysis, with a median observation time of 71.7 months. Forty-three patients (38.4%) were pathologically upstaged, and the pathologically upstaged group had a significantly higher SUVmax than the non-upstaged group (p = 0.024). Cox regression demonstrated that a SUVmax ≥ 5 was a significant independent prognostic factor for RFS (hazard ratio 6.698, 95% CI: 2.031-22.084, p < 0.001). In addition, there was a significant difference in the median RFS between the SUVmax ≥ 5 and SUVmax < 5 groups (48.1 versus 77.4 months, p < 0.001).
conclusionElevated preoperative PET SUVmax is associated with increased pathological upstaging, as well as a poorer RFS in clinical stage IA NSCLC. Although a PET SUVmax ≥ 5 was identified as a strong independent prognostic indicator of RFS in our cohort, this threshold should be interpreted cautiously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.